What is Transitional Cell Carcinoma? Signs, Risk Factors, and Treatment Explained

A cancer diagnosis is a life-altering event, and it is completely natural to feel overwhelmed, confused, or anxious. If you or a loved one has been diagnosed with transitional cell carcinoma (TCC), this guide is designed to provide clear, compassionate, and easy-to-understand information. Our goal is to help you better understand the condition, the available treatments, and what to expect as you move forward.

What Is Transitional Cell Carcinoma?

Transitional cell carcinoma (TCC) is a type of cancer that starts in the “transitional cells” that line the inside of certain organs. These special cells, also known as urothelial cells, can stretch and change shape as the organs they line fill and empty.

The most common place for TCC to form is in the bladder, accounting for over 90% of bladder cancers. However, it can also develop in other parts of the urinary system that are lined with these cells, including the kidneys (specifically the renal pelvis), the ureters (the tubes connecting the kidneys to the bladder), and the urethra (the tube through which urine exits the body).

The good news is that when detected early, especially in the bladder, TCC is highly treatable. Understanding the signs and seeking prompt medical attention is the first and most important step.

Types of Transitional Cell Carcinoma

While all transitional cell carcinomas originate from the same type of cell, they can be categorized based on how they grow and how deeply they have invaded the organ wall.This distinction is crucial for determining the best treatment plan.

1. Non-Muscle-Invasive Bladder Cancer (NMIBC):

This is the most common form of TCC, representing about 70-80% of all cases. In this type, the cancer cells are found only in the innermost lining of the bladder and have not yet grown into the bladder muscle. NMIBC is often described as either:

• Papillary: The tumors grow in a finger-like, mushroom-shaped pattern extending into the bladder cavity.
• Carcinoma in situ (CIS): The cancer cells are flat and do not form a tumor mass. This type is considered high-grade and has a higher risk of becoming invasive.

2. Muscle-Invasive Bladder Cancer (MIBC):

When tumor infiltrates the muscle layer, this type of TCC is more serious because the cancer has grown deeper, penetrating the muscle layer of the bladder wall. Because it has invaded the muscle, there is a higher risk of the cancer spreading to other parts of the body. MIBC requires more aggressive treatment.

What Are the Causes and Risk Factors for Transitional Cell Carcinoma?

While the exact cause of an individual’s cancer is often unknown, research has identified several key factors that significantly increase the risk of developing transitional cell carcinoma. These are often linked to damage to the transitional cells lining the urinary tract.

Lifestyle Risk Factors:

• Smoking: This is by far the most significant risk factor for TCC. Smokers are
  several times more likely to develop bladder cancer than non-smokers. The
  cancer-causing chemicals in tobacco smoke are absorbed into the bloodstream,
  filtered by the kidneys, and accumulate in the urine, damaging the transitional
  cells over time.
• Obesity: Some studies suggest that obesity may modestly increase the risk of
  bladder cancer, but smoking remains by far the strongest and most established
  risk factor.

Environmental and Occupational Risk Factors:

• Chemical Exposure: Certain chemicals used in the dye, rubber, leather, textile,
  and paint industries can increase the risk of TCC. Workers in these fields, as well
  as hairdressers, machinists, and truck drivers, may have a higher risk.
• Arsenic: Exposure to arsenic in drinking water is a known risk factor.

Medical Risk Factors:

• Chronic Bladder Inflammation: Chronic urinary tract infections, bladder
  stones, or long-term catheter use can lead to persistent inflammation, increasing
  the risk of TCC, particularly the squamous cell type.
• Previous Radiation Therapy: Patients who have had radiation to the pelvic
  area for a previous cancer may have a higher risk of developing TCC many years
  later.
• Certain Medications: The chemotherapy drug cyclophosphamide and the
  diabetes drug pioglitazone have been linked to an increased risk of TCC.

Genetic Risk Factors:

• Family History: Having a close family member with bladder cancer can slightly
  increase your risk, suggesting a genetic predisposition.
• Genetic Syndromes: Rare inherited syndromes like Lynch syndrome (HNPCC)
  and Cowden’s syndrome can also increase the risk of TCC.

It’s important to remember that having one or more of these risk factors does not
guarantee you will get TCC. However, being aware of them can help you take proactive
steps, such as quitting smoking, to lower your risk.

What Are the Symptoms of Transitional Cell Carcinoma?

Early detection of TCC is critical for a positive outcome. The most common symptom is
often the first and only sign, which is why it’s so important not to ignore it.

The most common early symptom is blood in the urine (hematuria). This is the hallmark
symptom of TCC. The blood may be visible, turning the urine pink, red, or dark brown.
In many cases, however, the blood is microscopic and can only be detected with a lab
test (urinalysis). This symptom is usually painless and may come and go, leading people
to delay seeking medical help.

Herald Hematuria: Watching the First sign of blood in urine is important.

Other less common symptoms include changes in urination such as:

• Frequent urination
• Urgent need to urinate
• Painful or burning sensation during urination (dysuria)
• Difficulty urinating or a weak urine stream

Advanced Symptoms:

If the cancer grows or spreads, more advanced symptoms may appear.

• Persistent pain in the lower back on one side or in the pelvic region.
• Swelling in the Legs or Feet
• Unexplained Weight Loss
• Loss of Appetite

These symptoms can also be caused by many other non-cancerous conditions, such as a
urinary tract infection or kidney stones. However, it is essential to see a doctor promptly
to get an accurate diagnosis. Ignoring these signs can lead to a delay in treatment, which
could allow the cancer to progress to a more advanced stage.

How Is Transitional Cell Carcinoma Diagnosed?

Diagnosing TCC involves a series of tests to confirm the presence of cancer and determine its location and extent. Your doctor will likely start with a physical exam and a discussion of your symptoms.

Common Diagnostic Tests:

1. Urine Tests:

• Urinalysis: A lab test to check for blood and other substances in your urine.
• Urine Cytology: A microscopic examination of urine to look for cancer cells.

2. Imaging Scans:

• CT (Computed Tomography) Scan: A CT scan of the abdomen and pelvis provides detailed cross-sectional images of the urinary tract, kidneys, and surrounding organs. It can help identify the tumor and see if the cancer has spread.
• MRI (Magnetic Resonance Imaging) Scan: An MRI uses magnetic fields and radio waves to create detailed images of soft tissues, which can be particularly useful for evaluating the depth of a tumor in the bladder wall.
• Ultrasound: An ultrasound uses sound waves to create images of the kidneys and bladder, which can help detect a mass.

3. Cystoscopy and Biopsy (The Gold Standard):

• Cystoscopy: This is the most definitive test. A urologist (a doctor specializing in the urinary system) inserts a thin, lighted tube with a camera (a cystoscope) through the urethra into the bladder. This allows the doctor to see the inside of the bladder and identify any abnormal areas.
• Biopsy: During the cystoscopy, the doctor can take a small tissue sample (biopsy) of any suspicious area. This sample is then sent to a pathologist for microscopic examination to confirm if it is cancer and what type it is. This procedure is known as a Transurethral Resection of Bladder Tumor (TURBT) and is often the first step in both diagnosis and treatment for early-stage TCC.

Staging and Grading of Transitional Cell Carcinoma

Once TCC is diagnosed, your medical team will “grade” and “stage” the cancer. This
process is crucial for creating the most effective treatment plan.

Grading:

This describes how aggressive the cancer cells appear under a microscope.

• Low-Grade: The cancer cells look very similar to normal transitional cells. They are slow-growing and are less likely to invade the muscle wall or spread.
• High-Grade: The cancer cells look very different from normal cells. They are fast-growing and are more likely to invade the muscle and spread to other parts of the body.

Staging:

This describes the extent of the cancer’s spread. The most common system is the TNM system, which stands for Tumor (T), Node (N), and Metastasis (M).

• Stage 0: Non-invasive cancer confined to the innermost lining.
• Stage I: The cancer has grown into the connective tissue beneath the lining but has not reached the muscle layer.
• Stage II: The cancer has invaded the muscle layer of the bladder wall.
• Stage III: The cancer has spread beyond the muscle layer to the fatty tissue surrounding the bladder.
• Stage IV: The cancer has spread to nearby lymph nodes or to distant parts of the body, such as the lungs, bones, or liver.

What Are the Treatment Options for Transitional Cell Carcinoma?

The treatment plan for TCC is highly personalized, depending on the stage and grade of
the cancer, as well as the patient’s overall health. A team of specialists, including urologists, medical oncologists, and radiation oncologists, will work together to determine the best course of action.

1. Surgery:

Surgery is the cornerstone of treatment for most stages of TCC.

• Transurethral Resection of Bladder Tumor (TURBT): This is the primary treatment for non-muscle-invasive TCC. The tumor is removed using a cystoscope inserted through the urethra. This is both a diagnostic and therapeutic procedure.
• Radical Cystectomy: For muscle-invasive TCC or high-grade, non-invasive tumors that are unresponsive to other treatments, the surgeon may need to remove the entire bladder and nearby lymph nodes. In men, the prostate is also removed, and in women, the uterus, ovaries, and a part of the vagina may be removed.
• Urinary Diversion: If the bladder is removed, a new way for the body to store and pass urine is created. This is known as urinary diversion.

2. Medical Treatment:

Medical treatments use drugs to kill cancer cells throughout the body.

• Intravesical Therapy: For early-stage TCC, drugs are put directly into the bladder through a catheter. The most common is a type of immunotherapy called Bacillus Calmette-Guerin (BCG), which uses a weakened bacteria to activate the immune system to fight cancer. Apart from BCG, intravesical chemotherapy agents like mitomycin C or gemcitabine may be used, especially for low- to intermediate-risk disease.
• Chemotherapy: Chemo uses powerful drugs to kill cancer cells. It can be given intravenously (IV) and is often used for muscle-invasive TCC. It may be given before surgery (neoadjuvant) to shrink the tumor or after surgery (adjuvant) to kill any remaining cancer cells. It is also the main treatment for advanced, metastatic TCC. HIVEC stands for Hyperthermic Intravesical Chemotherapy. It’s a medical procedure used to treat non-muscle invasive bladder cancer.

This treatment involves:

1. Heating: a chemotherapy drug (like mitomycin C) to a specific temperature, typically around 43°C.
2. Delivering: the heated drug directly into the bladder (intravesical).

The heat enhances the drug’s effectiveness, improving its ability to kill cancer cells. HIVEC is considered a bladder-sparing therapy for patients who are not candidates for or choose not to have more extensive surgery.

• Immunotherapy: Immunotherapy drugs, such as checkpoint inhibitors, help the body’s own immune system recognize and attack cancer cells. This is a common treatment for advanced TCC that has spread.
• Targeted Therapy: These newer drugs are designed to target specific weaknesses in cancer cells. They are an option for advanced TCC, particularly for patients who have specific genetic mutations.

3. Radiation Therapy:

Radiation therapy is typically used as part of a bladder-preserving trimodality approach (TURBT + chemotherapy + radiation) for carefully selected patients who wish to avoid or are unfit for cystectomy.

Prognosis and Survival Rates for Transitional Cell Carcinoma

The prognosis (the likely outcome of the disease) for TCC is highly dependent on the stage and grade at diagnosis. It is important to remember that these statistics are based on large populations and cannot predict an individual’s outcome.

Prognosis Based on Stage:

• Localized TCC: The 5-year survival for non-muscle-invasive bladder cancer (stage 0–I) is high, often >85–90%. However, recurrence is common, requiring lifelong surveillance.
• Regional TCC: If the cancer has spread to nearby tissues or lymph nodes, the 5- year survival rate is lower but still significant.
• Distant TCC: For cancer that has spread to distant parts of the body, the prognosis is less favorable, but new treatments are constantly improving outcomes.

The most important factors affecting prognosis are the stage, the grade, and whether the
cancer has spread. Timely diagnosis and expert, personalized care are the best ways to
improve your chances of a positive outcome.

Screening and Prevention of Transitional Cell Carcinoma

There is no routine screening for TCC in the general population. The most effective way to protect yourself is through prevention and early detection.

Prevention Strategies:

• Stop Smoking: The single most important step you can take to prevent TCC is to quit smoking.
• Be Mindful of Occupational Exposures: If you work with chemicals linked to TCC, follow all safety protocols, including wearing protective gear.
• Stay Hydrated: Drinking plenty of water can help flush out toxins from the bladder.

Early Detection:

• Pay Attention to Your Body: Do not ignore blood in your urine, even if it is painless and comes and goes.
• Consult a Doctor: If you notice any of the symptoms of TCC, especially blood in your urine, see a doctor immediately.

For International Patients: A Seamless Journey to Apollo Hospitals

Apollo Hospitals is a global leader in providing world-class cancer care to international patients. Our dedicated International Patient Services team is here to ensure your entire
experience, from your first contact to your return home, is smooth and stress-free.

Our Comprehensive Services for International Patients Include:

• Personalized Case Management: A dedicated patient coordinator will be your single point of contact, helping you with everything from initial consultations to post-treatment follow-up.
• Visa and Travel Assistance: We provide visa invitation letters and assist with travel arrangements to make your journey easy.
• Accommodation and Logistics: We can help you find suitable accommodation for you and your family near the hospital.
• Language Support: Our team offers translation and interpretation services to ensure clear communication with your medical team.
• Teleconsultations: We can arrange for you to have a video consultation with our specialists before you travel to discuss your case and treatment plan.

About Apollo Proton Cancer Centre

Apollo Proton Cancer Centre (APCC) is the first proton therapy centre in India. APCC has a fully integrated treatment suite that offers the most advanced treatment in surgical, radiation, and medical oncology procedures. True to the Apollo Pillars of Expertise and Excellence, the Centre brings together a powerful team of clinicians renowned globally for cancer care.

At Apollo Proton Cancer Centre (APCC), we combine advanced technology with globally renowned clinical expertise to deliver superior outcomes and improved quality of life to our patients.